Trials / Completed
CompletedNCT06315699
Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome
Randomized, Double-blind, Controlled Study of Clomastine Fumarate in the Treatment of Williams Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 3 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
This study focuses on therapeutic targets for cognitive, motor, and social impairments in Williams syndrome by reversing brain myelin defects caused by GTF2I. The primary objective of the study was to test and evaluate the initial efficacy and safety of Clomastine fumarate in the treatment of Williams syndrome.
Detailed description
The primary objective of this study was to evaluate the initial efficacy and safety of Clomastine fumarate in the treatment of Williams syndrome. The secondary objective is to study Clomastine fumarate in relation to mechanisms of action, safety, and/or pathological mechanisms. This study was a randomized, cross-over, placebo-controlled design. Each participant will be randomly assigned to two groups through baseline assessment (see study results), with Group A receiving the FDA-approved drug Clemastine at a weight-dependent dose (see dosing table below) for the first cycle and placebo for the second cycle. Group B will be treated with placebo for the first cycle and the FDA-approved drug Clemastine for the second cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clemastine Fumarate Tablets | clemastine fumarate (0.178 mg/kg/day), three months |
| DIETARY_SUPPLEMENT | corn starch tablets | The dose was administered 2mg once daily in a double-blind random crossover method |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2025-03-02
- Completion
- 2025-12-30
- First posted
- 2024-03-18
- Last updated
- 2026-03-19
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06315699. Inclusion in this directory is not an endorsement.